about
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.A-type lamins and signaling: the PI 3-kinase/Akt pathway moves forward.Targeting PI3K/AKT/mTOR network for treatment of leukemia.An interaction study in mammalian cells demonstrates weak binding of HSPB2 to BAG3, which is regulated by HSPB3 and abrogated by HSPB8.Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia.Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cells.Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.Proposal of a Novel Natural Biomaterial, the Scleral Ossicle, for the Development of Vascularized Bone Tissue In Vitro.Inhibition of Ras-mediated signaling pathways in CML stem cells.Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit
P50
Q36738818-9E81AD5E-ABAD-4C7E-8D2F-5731282BC109Q37500299-C658FD9C-67BB-4FBC-8FAC-02E44F691A03Q38364871-04E6F97B-65EB-4640-878B-EB3B79D38B3AQ38970552-3884D055-6FB8-4F7C-BF15-5199A455652DQ39623680-79072250-7B03-4CF0-82B3-3AE25FAEA203Q39937276-40C4AC2A-7BE5-47F7-9C99-69E0B2BFD5B3Q39945195-2AF7E4B9-34B6-4DA3-9275-C059388EEF79Q39986126-B8E2819A-A8CB-43D0-B3DF-D9A6C6FCBA4AQ40135888-35E97B9C-A215-4065-82E1-09BA5BEEB2A3Q42026999-4D39E4DE-B5F5-40FA-823E-8A305346C8ACQ52732001-7D73DD9A-A74C-4A75-B3BB-CB9ADAB5ACB5Q53314331-246DA165-A58A-4E39-AAA7-CFA1E5412B1DQ54362642-D211D9CD-3FEC-426A-A9A5-9C855C19DFA8Q90630492-F65A23BF-1484-4385-8377-0C54DA970537
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jessika Bertacchini
@ast
Jessika Bertacchini
@en
Jessika Bertacchini
@es
Jessika Bertacchini
@nl
type
label
Jessika Bertacchini
@ast
Jessika Bertacchini
@en
Jessika Bertacchini
@es
Jessika Bertacchini
@nl
prefLabel
Jessika Bertacchini
@ast
Jessika Bertacchini
@en
Jessika Bertacchini
@es
Jessika Bertacchini
@nl
P106
P1153
24472572300
P31
P496
0000-0001-9218-9215